Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin

One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]). In this follow-up study, children from USA or Puerto Rico, who had received one dose of M-M-R...

Descripción completa

Detalles Bibliográficos
Autores principales: Berry, Andrea A., Abu-Elyazeed, Remon, Diaz-Perez, Clemente, Mufson, Maurice A., Harrison, Christopher J., Leonardi, Michael, Twiggs, Jerry D., Peltier, Christopher, Grogg, Stanley, Carbayo, Antonio, Shapiro, Steven, Povey, Michael, Baccarini, Carmen, Innis, Bruce L., Henry, Ouzama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512763/
https://www.ncbi.nlm.nih.gov/pubmed/28481690
http://dx.doi.org/10.1080/21645515.2017.1309486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512763/
https://www.ncbi.nlm.nih.gov/pubmed/28481690
http://dx.doi.org/10.1080/21645515.2017.1309486

Ejemplares similares